Recombinant human interferon-α1b inhibits SARS-CoV-2 better than interferon-α2b in vitro
Dear Editor,
The coronavirus disease 2019(COVID-19)outbreak,has spread across the world(Wu et al.,2020).The causative agent of COVID-19,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2),is highly pathogenic and infectious,which become a major public health hazard that has had a devastating social and economic impact worldwide(Li Q.Q.et al.,2020).
Variants of the virus have emerged that behave differently(CDC 2021;Gobeil et al.,2020;Leung et al.,2021).Some of them show increased infectivity(Li Q.et al.,2020;Zhang et al.,2020)and may escape from neutralizing antibodies(Weisblum et al.,2020).Various vaccines have been developed and marketed for COVID-19.However,there is a shortage of specific drugs to treat this novel virus and there is an urgent need for effective broad-spectrum anti-viral drugs to treat COVID-19 and its variants.
sars-cov-2、vitro、human、than、better、inhibits、interferon-、recombinant
37
R563.1;R373.1;R978.7
2022-09-14（万方平台首次上网日期，不代表论文的发表时间）
共4页
295-298
